Mounjaro and Sleep Apnoea: What New Research Shows

If you have obstructive sleep apnoea (OSA) and are also living with overweight or obesity, weight loss could potentially improve more than the number on the scales.

New research published in September 2026 has reviewed the growing evidence around GLP-1-based weight-loss medicines and sleep apnoea, with particularly promising findings for tirzepatide, the active ingredient in Mounjaro.

So could Mounjaro help people with obesity-related sleep apnoea?

What is obstructive sleep apnoea?

Obstructive sleep apnoea occurs when the upper airway repeatedly narrows or closes during sleep, temporarily interrupting breathing.

Common symptoms include:

loud snoring
waking or gasping during sleep
morning headaches
poor concentration
significant daytime tiredness.

OSA is also associated with longer-term health risks including high blood pressure and cardiovascular disease.

Obesity is one of the most important modifiable risk factors for OSA, with excess tissue around the neck and upper airway contributing to narrowing during sleep.

What did the new research find?

A new review published in JAMA Otolaryngology–Head & Neck Surgery examined the evidence for GLP-1-based medicines in people with obstructive sleep apnoea.

Across several meta-analyses, these treatments were associated with reductions in the apnoea-hypopnoea index (AHI) - the number of times breathing becomes significantly reduced or stops during each hour of sleep.

Some of the strongest evidence came from the SURMOUNT-OSA trials, which studied tirzepatide in adults living with obesity and moderate-to-severe obstructive sleep apnoea.

Tirzepatide reduced breathing interruptions by approximately 20–24 events per hour compared with placebo.

In the two trials, around 43–52% of participants treated with tirzepatide reached either remission or mild, non-symptomatic OSA, depending on the study.

These findings suggest that clinically meaningful weight loss may substantially improve sleep apnoea for some people whose condition is closely linked to obesity.

Does Mounjaro treat sleep apnoea?

In the UK, Mounjaro is licensed for weight management in eligible adults, including weight loss and weight maintenance.

Obstructive sleep apnoea is specifically recognised in the Mounjaro product information as an example of a weight-related health condition.

However, this does not mean patients should start Mounjaro simply as a replacement for established sleep-apnoea treatment.

What about CPAP?

CPAP (continuous positive airway pressure) remains an important treatment for moderate and severe obstructive sleep apnoea.

The new review found that CPAP was still more effective at immediately reducing breathing interruptions than tirzepatide.

The important difference is that weight-management treatment may address one of the underlying drivers of obesity-related OSA, while CPAP physically keeps the airway open while you sleep.

For some patients, these approaches may therefore be complementary rather than competing treatments.

If you currently use CPAP, do not stop it simply because you have started losing weight.

Your sleep team should reassess your condition before any sleep-apnoea treatment is changed.

Is the improvement simply because people lose weight?

Weight loss appears to be a major reason for the improvement.

Reducing fat around the neck, tongue and upper airway can help create more room for airflow during sleep.

Researchers are also investigating whether GLP-1 pathways may have additional effects on breathing control, inflammation or airway function, but this remains an emerging area of research.

For now, the clearest evidence is that substantial weight reduction can improve obesity-related obstructive sleep apnoea.

What does this mean for people with obesity and sleep apnoea?

It reinforces an important point:

Weight management is about much more than appearance.

For appropriate patients, losing clinically meaningful weight may improve several areas of health at the same time, potentially including metabolic health, cardiovascular risk factors, mobility and the severity of obesity-related sleep apnoea.

And once those health improvements have been achieved, maintaining the weight loss matters too.